Poland· PL-100473669
Vabysmo
A faricimab product containing faricimabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Faricimab is registered in 14 of 19 countries.
Countries holding a registration under ATC S01LA09 (faricimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Faricimab · ATC S01LA09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Faricimabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- S01LA09
- ATC class
- Faricimab
- Defined daily dose
- 0.0357 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin07613326050708
- gtin07613326077385
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Faricimab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVABYSMO 120 MG/ML SOLUCION INYECTABLERoche Registration Gmbh
- SwitzerlandVabysmo 6 mg/0,05 ml, InjektionslösungRoche Pharma (Schweiz) AG
- CzechiaVABYSMORoche Registration GmbH, Grenzach-Wyhlen
- SwedenVABYSMO 120 mg/ml Injektionsvätska, lösningRoche Registration GmbH
- NorwayVabysmoRoche Registration GmbH
- BelgiumVabysmo 120 mg/mlRoche Registration
- IrelandVabysmo 120 mg/mL solution for injectionRoche Registration GmbH
- IcelandVabysmoRoche Registration GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vabysmo
- Liechtenstein · Vabysmo
- Norway · Vabysmo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7234306e-4539-4ae0-82c7-2871be1b1998 GET /v1/drugs/7234306e-4539-4ae0-82c7-2871be1b1998?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "120 mg/ml",
"packaging": "07613326050708 ¦ Rpz ¦ EU/1/22/1683/001 ¦ 146956\n1 fiol. 0,24 ml ¦ 1 igła \n07613326077385 ¦ Rpz ¦ EU/1/22/1683/002 ¦ 160097\n1 igła ¦ 1 amp.-strzyk.",
"substance": "Faricimabum 120 mg/ml",
"common_name": "Faricimabum",
"pl_product_id": "100473669",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about faricimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.